Uncategorized

Semaglutide reduces cardiovascular events by 20% in high-risk patients but carries specific cardiac contraindications you must know before starting

Semaglutide reduces sleep apnea severity by 50–60% through weight loss and airway pressure reduction, with effects visible within 12–20 weeks of treatment.

Semaglutide reduces systolic blood pressure by 5–8 mmHg on average through weight loss and improved insulin sensitivity—beyond what weight reduction alone

Semaglutide NAFLD treatment shows 59% NASH resolution versus 17% placebo in clinical trials, targeting liver inflammation through mechanisms beyond weight

Semaglutide cancer risk research shows no causal link in humans — animal thyroid tumor data doesn’t translate to clinical use. Here’s what matters.

Semaglutide carries a boxed warning for thyroid C-cell tumors based on rodent studies — but human clinical trials show no confirmed cases. Here’s what

Semaglutide carries a black box warning for thyroid C-cell tumor risk. Understand who should avoid GLP-1 therapy and what the evidence actually shows.

Semaglutide reduces chronic inflammation by lowering inflammatory cytokines IL-6 and TNF-alpha while improving insulin sensitivity and endothelial

Semaglutide reduces liver fat by 30–40% in clinical trials through weight loss and direct anti-inflammatory effects — not through metabolism alone.